Genocea Biosciences, Inc. (NASDAQ:GNCA) Q2 2020 Earnings Conference Call - Final Transcript
Jul 23, 2020 • 08:30 am ET
Good morning, and welcome to the Genocea Second Quarter 2020 Q2 Conference Call. [Operator Instructions] Please be advised the call is being recorded at the company's request. At this time, I'd like to turn the call over to Dan Ferry of LifeSci Advisors. Please proceed.
Thank you, operator, and good morning, everyone. Earlier today, we issued a press release that outlines the topics we plan to discuss today. This release is available at genocea.com under the Investors tab. During the call today, Chip Clark, President and CEO, will provide a brief corporate update and the company's Chief Financial Officer, Diantha Duvall, will review the financial results. After the prepared remarks, we will open up the call for Q&A and Chip Diantha, Tom Davis, Genocea's Chief Medical Officer; and Jessica Flechtner, Genocea's Chief Scientific Officer, will then be available to answer your questions.
Before we begin, I would like to remind everyone that statements made during this conference call relating to Genocea's expected future performance, future business prospects or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from those forecast due to the impact of many factors beyond the control of Genocea. Genocea expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to the risk factors set forth in Genocea's 2019 annual report on Form 10-K, and other periodic reports filed with the Securities and Exchange Commission. It is now my pleasure to pass the call over to Chip.
Thanks, Dan, and thank you all for joining us today. Genocea has had an active and productive second quarter, demonstrating important progress across the company. There is much to recap on today's call, and we are especially excited about the path forward for our two differentiated clinical-stage programs; GEN-009, our neoantigen vaccine, and GEN-011, our neoantigen cell therapy.
First, I'd like to discuss the GEN-009 vaccine program. On July 30, we will present initial clinical data on the first five patients from Part B of our ongoing Phase I/IIa clinical trial with Dr. Maura L. Gillison, a renowned professor of Medicine at the MD Anderson Cancer Center and the lead investigator of the trial. Part B of the study is exploring the combination of GEN-009 and immune checkpoint-inhibitor-based regimens in advanced solid tumors. To register for the event, please visit the Investors section of our website. We shared long-term follow-up data from Part A of the same trial at ASCO's 2020 Virtual Scientific Program, evaluating the duration of immune responses and clinical outcomes for eight participants. We are encouraged by the results, seven out of eight patients treated are without disease progression at 1-year median follow-up. In addition, we observed that GEN-009 drove broad sustained T-cell responses to neoantigens identified